Raymedica Launches Official Web Site, Providing Nucleus Arthroplasty™ Technology for Degenerative Disc Disease (DDD)

MINNEAPOLIS, August 23 - After a successful three-month trial of the beta version of Raymedica.com (www.raymedica.com), the company is pleased to announce that it has now launched its - Nucleus Arthroplasty™ Technology Web site.

An estimated 30 million people in the United States report experiencing back pain each year. Of this number, 4.5 million continue to experience back pain after receiving conservative treatment, such as physical therapy and use of medication(s). Only a small percentage of this group for whom conservative treatment for Degenerative Disc Disease (DDD) is unsuccessful will be best suited for more aggressive treatments such as Total Disc Replacement (TDR) and spinal fusion.

One of the main reasons why Raymedica.com was launched is the belief that a much larger percentage of patients can be more effectively treated with a Nucleus Arthroplasty™ technology solution. Raymedica’s Nucleus Arthroplasty™ system offer several benefits over spinal fusion and other procedures, including better long-term clinical outcomes, less invasive surgical techniques, shorter recovery times and maintains a more normal range of motion.

John J. Viscogliosi, Chairman and CEO, “Patients, surgeons, and educational institutions are now in an excellent position to fully and easily access valuable information on Nucleus Arthroplasty™ technology using web services available on Raymedica.com.” Mr. Viscogliosi continued “we believe that as spinal arthroplasty device technology advances, the market for our technology will expand and erode the use of more invasive treatments for DDD, such as TDR’s and spinal fusion.”

About Raymedica, Inc.
Raymedica the “Pioneer in Nucleus Arthroplasty™” develops, manufactures and markets medical device systems designed to treat patients with degenerative disc disease that have not responded to non-surgical treatment. Raymedica pioneered and is the scientific, clinical and regulatory leader in the nucleus replacement segment of the non-fusion spine market. Raymedica devices have been used in more than 3,500 procedures globally. Raymedica’s products are currently available worldwide, but are limited to investigational use only in the United States. For more information, visit the Company's website at http://www.raymedica.com.